Teriparatide

Treatment for Osteoporosis

Typical Dosage: 20 mcg subcutaneous injection once daily

Effectiveness
70%
Safety Score
55%
Clinical Trials
131
Participants
5.5K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
20 mcg subcutaneous injection once daily
Time to Effect
6-12 months
Treatment Duration
Up to 2 years lifetime maximum
Evidence Quality
HIGH
Number Needed to Treat (NNT)
11(Treat 11 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
500(Treat 500 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$8,000
Monitoring:$400
Side Effect Mgmt:$100
Total Annual:$8,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POOR
ICER
$200,000/QALY
QALYs Gained
0.3
Teriparatide Outcomes

for Osteoporosis

Efficacy Outcomes
Overall Effectiveness
+70%
Common Side Effects
Nausea
+9%
Leg cramps
+7%
Dizziness
+9%
Hypercalcemia
+7%
Hypotension
+2%

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov

Completed Clinical Trials
14 completed trials for Teriparatide in Osteoporosis

A Comparison of PF708 and Forteo in Osteoporosis Patients

NCT03002428COMPLETEDPHASE3
View Study
181 participants
INTERVENTIONAL
Birmingham, United States +25 more
Started: Dec 1, 2016

Teriparatide (Forsteo) Treatment in Postmenopausal Women: Mechanism of Action

NCT01293292COMPLETEDPHASE4
View Study
19 participants
INTERVENTIONAL
Sheffield, United Kingdom
Started: Jan 1, 2011

A Comparison Study of PF708 and Forteo in Healthy Subjects

NCT02656810COMPLETEDPHASE1
View Study
70 participants
INTERVENTIONAL
Evansville, United States
Started: Dec 1, 2015

Dose Ranging Study - Macroflux Parathyroid Hormone (PTH) in Postmenopausal Women With Osteoporosis

NCT00489918COMPLETEDPHASE2
View Study
165 participants
INTERVENTIONAL
Started: Jun 1, 2007

Evaluation of the Effects of Teriparatide on Skeleton Images in Postmenopausal Women With Osteoporosis

NCT00259298COMPLETEDPHASE4
View Study
12 participants
INTERVENTIONAL
London, United Kingdom
Started: Nov 1, 2005

Study of the Experience of Patients With Osteoporosis Using the Forteo B Pen to Self Administer Once Daily Teriparatide Therapy

NCT00577863COMPLETEDPHASE3
View Study
200 participants
INTERVENTIONAL
Huntsville, United States +17 more
Started: Jan 1, 2008

Study of FORTEO Use in Subjects in the Community Setting

NCT01078805COMPLETED
View Study
4.17K participants
OBSERVATIONAL
Lakewood, United States
Started: Aug 1, 2003

Teriparatide Treatment in Patients With Inherited Osteoporosis

NCT01360424COMPLETEDPHASE4
View Study
6 participants
INTERVENTIONAL
Helsinki, Finland
Started: May 1, 2011

Combined Administration of Teripapartide and Antiresorptive Agents in Postmenopausal Osteoporosis

NCT01535027COMPLETEDPHASE4
View Study
125 participants
INTERVENTIONAL
Vienna, Austria
Started: Mar 1, 2006

A Study for the Transdermal Application of Teriparatide

NCT01011556COMPLETEDPHASE2
View Study
233 participants
INTERVENTIONAL
Buenos Aires, Argentina +17 more
Started: Nov 1, 2009

Bioequivalence Study of SAL001 and FORSTEO in Healthy Chinese Adults

NCT04747392COMPLETEDPHASE1
View Study
64 participants
INTERVENTIONAL
Guangzhou, China
Started: Aug 19, 2020

Efficacy & Safety of ViaDerm-hPTH(1-34) Compared to Forteo SC in Postmenopausal Women With Osteoporosis

NCT00535860COMPLETEDPHASE2
View Study
104 participants
INTERVENTIONAL
Hradec Králové, Czechia +9 more
Started: Apr 1, 2008

A Study Using Imaging Technology to Measure Changes in Bone Structure After Treatment With Teriparatide

NCT00557310COMPLETEDPHASE4
View Study
35 participants
INTERVENTIONAL
Tucson, United States +5 more
Started: Nov 1, 2007

Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis

NCT00926380COMPLETEDPHASE2
View Study
94 participants
INTERVENTIONAL
Boston, United States
Started: Jun 1, 2009
Showing 20 of 132 total trials